Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Fexuprazan (DWP14012) in Acute or Chronic Gastritis
NCT04341454Phase 3Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- Jun 2020
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fexuprazan in acute gastritis and chronic gastritis (3 arms), sponsored by Daewoong Pharmaceutical. Primary endpoint: Improvement rate of gastric mucosal erosion at 2 weeks. Started Jun 2020; status: completed.
02
Drugs
fexuprazan
03
Conditions
acute gastritischronic gastritis
Beyond the preview
Go deeper on NCT04341454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04341454.